First human test begins for new lung disease drug
NCT ID NCT07116889
Summary
This is the first study in humans to test the safety and side effects of a new drug called GB-0895. It involves 156 adults with mild to moderate asthma or COPD. Researchers will give different doses to see how the body handles the drug and monitor for any problems.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alcanza
DeLand, Florida, 32720, United States
-
Charite Research Organization GmbH
Berlin, Germany
-
DM Clinical Research
Tomball, Texas, 77375, United States
-
Fraunhofer Institut fur Toxikologie and Experimentelle Medizin (ITEM)
Hanover, Germany
-
Hammersmith Medicines Research
London, United Kingdom
-
IKF Pneumologie
Frankfurt, Germany
-
Medicines Evaluation Unit (MEU)
Manchester, United Kingdom
-
Miami Research Institute of South Florida
Miami, Florida, 33173, United States
-
Nucleus Network
Saint Paul, Minnesota, 55114, United States
-
Omega Research
Orlando, Florida, 32808, United States
-
Queen Anne Street Medical Center
London, United Kingdom
-
Simbec-Orion Clinical Development
Merthyr Tydfil, United Kingdom
-
Southeastern Research Center
Winston-Salem, North Carolina, 27103, United States
Conditions
Explore the condition pages connected to this study.